Aug 7 (Reuters) – Sino Biopharmaceutical Limited: * NMPA APPROVES BENMELSTOBART WITH CHEMOTHERAPY FOLLOWED BY ANLOTINIB FOR FIRST-LINE SQ-NSCLC Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)